Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2022-03-08 Share Issue/Capital Cha…
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
Approval of prospectus for BIOPORTO A/S; Shares
Share Issue/Capital Change Classification · 100% confidence The document is a formal 'Prospectus' issued by BioPorto A/S regarding a rights issue and the admission of new shares to trading. It contains detailed information on the offering, risk factors, company business, and financial information, which is characteristic of a securities prospectus. According to the provided filing categories, a prospectus for a capital increase/share offering falls under the 'Share Issue/Capital Change' (SHA) category.
2022-03-08 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 98% confidence The document explicitly announces a 'rights issue with pre-emptive subscription rights' and details the terms, subscription price, ratio, and timetable for issuing new shares. This activity directly relates to changes in the company's capital structure and fundraising efforts. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although a Prospectus is mentioned, the document itself is the announcement detailing the capital change, not just a notice that a report is available (which would be RPA/RNS).
2022-03-07 English
BioPorto A/S publishes prospectus in connection with a rights issue with pre-emptive subscription rights for its existing shareholders
Capital/Financing Update Classification · 98% confidence The document is an official announcement from BioPorto A/S regarding a rights issue (a capital increase) for existing shareholders. It details the subscription price, ratio, timeline, and the purpose of the offering (capital resources). While it mentions a prospectus, the document itself is the primary announcement of the capital change/share issue, not just a notice that a report is available. Therefore, it fits best under the 'Share Issue/Capital Change' category.
2022-03-07 Danish
Share Issue/Capital Change 2022
Share Issue/Capital Change Classification · 99% confidence The document is an announcement dated March 7, 2022, detailing several key corporate actions: 1) Intention to initiate a rights issue (a capital/financing activity) to raise DKK 100.4M. 2) Updates on clinical trials for The NGAL Test. 3) Financial estimates for 2021 and guidance for 2022. 4) Changes to the company calendar, including the postponement of the Annual Report and AGM. The primary focus is the announcement of the rights issue and the associated capital raising plan, which strongly aligns with the 'Capital/Financing Update' definition. While it mentions financial estimates (ER/IR content) and postpones the AGM (AGM-R content), the central, actionable news item driving the announcement is the capital raise via a rights issue. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-03-07 English
BioPorto announces intention to initiate a rights issue with expected gross proceeds of up to approximately DKK 100.4M, updates on status of The NGAL Test clinical trials, and announces its financial
Capital/Financing Update Classification · 95% confidence The document is a corporate announcement regarding a planned rights issue, financial guidance, and clinical trial updates. While it contains financial estimates, it is not the financial report itself, but rather an announcement of corporate actions and future plans. It includes a link to an attachment and is structured as a regulatory news release. Therefore, it fits best as a general regulatory filing (RNS) or a capital update, but given the broad scope of the announcement (rights issue, guidance, and calendar changes), it is classified as a regulatory filing.
2022-03-07 Danish
In an effort to prioritize Emergency Use Authorizations (EUA), the FDA does not recommend that BioPorto pursue an EUA for its NGAL assay for the prediction of renal replacement therapy in COVID-19 pa
Regulatory Filings Classification · 95% confidence The document is a short announcement (2667 characters) from BioPorto regarding a regulatory update from the FDA concerning an Emergency Use Authorization (EUA) application. It does not fit into specific categories like financial reports, board changes, or share transactions. As it is a general regulatory update regarding company operations and FDA guidance, it falls under the fallback category of Regulatory Filings (RNS).
2021-11-19 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.